Health: Mental Health News

Today is March 19, 2024. All times in Eastern Daylight Time.

New Research Shows the PrecivityAD2™ Blood Test Has High Accuracy Compared to Amyloid PET Scans in Individuals with Cognitive Impairment

03/18/2024 - 12:33 PM

BUSINESS WIRE
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion

03/18/2024 - 09:52 AM

BUSINESS WIRE
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio

03/18/2024 - 08:44 AM

BUSINESS WIRE
Workers Expect Employers to Care About Their Lives At and Outside of Work Amid a State of Permacrisis

03/18/2024 - 08:00 AM

BUSINESS WIRE
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas

03/18/2024 - 07:30 AM

BUSINESS WIRE
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer

03/18/2024 - 07:00 AM

BUSINESS WIRE
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older

03/15/2024 - 04:30 PM

BUSINESS WIRE
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03/15/2024 - 04:05 PM

BUSINESS WIRE
Anthem Blue Cross and Blue Shield Foundation Awards $11 Million to Community Partners in New York

03/15/2024 - 10:00 AM

BUSINESS WIRE
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder

03/15/2024 - 07:30 AM

BUSINESS WIRE
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement

03/15/2024 - 07:00 AM

BUSINESS WIRE
Cybin berichtet über ein positives Treffen mit der FDA zum Ende der Phase 2 für CYB003 bei schweren depressiven Störungen und über die Planung eines Programms der Phase 3

03/14/2024 - 05:48 PM

BUSINESS WIRE
Cybin annonce une réunion positive avec la FDA à la fin de la phase 2 pour le CYB003 dans le trouble dépressif majeur et la conception du programme de phase 3

03/14/2024 - 04:28 PM

BUSINESS WIRE
Lightning Step Appoints Tanya Earles as New Chief Operating Officer

03/14/2024 - 04:23 PM

BUSINESS WIRE
Ontrak to Participate at the 36th Annual Roth Conference

03/14/2024 - 04:05 PM

BUSINESS WIRE
Cambia Health Foundation Releases 2023 Community Impact Report

03/14/2024 - 03:30 PM

BUSINESS WIRE
Cybin anuncia una reunión positivo de fin de fase 2 con la FDA para el uso de CYB003 en el trastorno depresivo mayor, así como el diseño del programa de fase 3

03/14/2024 - 02:25 PM

BUSINESS WIRE
Cybin kondigt positieve vergadering aan het einde van Fase 2 met FDA aan voor CYB003 bij depressieve stoornissen en het programmaontwerp voor Fase 3

03/14/2024 - 02:25 PM

BUSINESS WIRE
Cybin annuncia l’esito positivo di una riunione con la FDA sul termine della fase 2 riguardante CYB003 per il trattamento del disturbo depressivo maggiore e il progetto del programma di fase 3

03/14/2024 - 01:58 PM

BUSINESS WIRE
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

03/14/2024 - 09:34 AM

BUSINESS WIRE
Relias’ Dementia Care Specialist Training Recognized by the Alzheimer’s Association® Curriculum Review

03/14/2024 - 09:15 AM

BUSINESS WIRE
Morgan Stanley Announces Children’s Mental Health Innovation Award Winners and Launches Leadership Learning Series

03/14/2024 - 09:00 AM

BUSINESS WIRE
Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider

03/14/2024 - 07:30 AM

BUSINESS WIRE
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

03/14/2024 - 07:30 AM

BUSINESS WIRE
Cybin reçoit la désignation de thérapie innovante de la FDA pour sa molécule psychédélique CYB003 et annonce des données de durabilité positives à quatre mois pour le traitement du trouble dépressif majeur

03/13/2024 - 06:47 PM

BUSINESS WIRE

1 2 3 4 5 6 7 8

Next »

Search